Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 42

Trial Status

Recruiting1
Other1

Role Distribution

Other Roles2

Activity Timeline

Clinical Trials (2)

NCT05355350Phase 4Withdrawn
PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections
BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
StudydirectorStart date: 2022-07-01
NCT03671967Phase 4Recruiting
PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
StudydirectorStart date: 2019-05-01

Research Network

Collaboration Network

7 collaborators·17 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Rabin Medical Center, Beilinson Campus

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Roni Bitterman, MD

Rambam Health Care Campus

Moderately Similar
2 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 2 trials
Similarity Score38%

Mical Paul, MD

Rambam Health Care Campus

Moderately Similar
4 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 2 trials
Similarity Score38%

Cristina Mussini, MD

University of Modena and Reggio Emilia

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 1 trial
Similarity Score34%

Alaa Atamna, MD

Rabin Medical Center, Beilinson Campus

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Hadassah Medical OrganizationRabin Medical Center+2 more
Collaborated on 1 trial
Similarity Score34%

Leonard Leibovici, MD

Rabin Medical Center

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Canadian Institutes of Health Research (CIHR)Hadassah Medical Organization+9 more
Collaborated on 1 trial
Similarity Score34%

Dafna Yahav, MD

Sheba Tel HaShomer Medical Campus

Moderately Similar
1 trials

Shared therapeutic areas:

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections

Worked with same sponsors:

Hadassah Medical OrganizationRabin Medical Center+2 more
Collaborated on 1 trial
Similarity Score34%

Benoit PILMIS, MD

Fondation Hôpital Saint-Joseph

Related
8 trials

Shared therapeutic areas:

BacteremiaEnterobacteriaceae Infections
Similarity Score20%

Yohei Doi, MD

University of Pittsburgh

Related
8 trials

Shared therapeutic areas:

BacteremiaEnterobacteriaceae Infections
Similarity Score20%

Zhaohui Zhu

Peking Union Medical College Hospital

Related
7 trials

Shared therapeutic areas:

Enterobacteriaceae Infections
Similarity Score10%

Evangelos Giamarellos-Bourboulis, MD,PhD

Hellenic Institute for the Study of Sepsis

Related
3 trials

Shared therapeutic areas:

Bacteremia
Similarity Score10%

Publications (0)

No publications found for this investigator.

Clinical Trials (2)

Showing 2 of 2 trials

NCT05355350Phase 4StudyDirector

PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
Withdrawn
NCT03671967Phase 4StudyDirector

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

BacteremiaBeta Lactam Resistant Bacterial InfectionEnterobacteriaceae Infections
Recruiting

All 2 trials loaded